Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7ZM1H)

Drug Name

BHT-3009 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myelin basic protein (MBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBI-5788	DMH9JFZ	Multiple sclerosis	8A40	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00382629) BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health.
2	BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70.
3	NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.